Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Immunomic Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10820
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Immunomic Therapeutics Inc (ITI) is a clinical-stage biotechnology company that develops patented lysosomal-associated membrane protein or lamp technology based nucleic acid immunotherapy platforms. The company’s vaccines utilize the body’s natural biochemistry to develop immune response including antibody production, cytokine release and critical immunological memory. Its oncology pipeline products at various stages of development include ITI-1000, ITI-1001, ITI-2000, ITI-3000, ITI-4000, ITI-5000, and ITI-6000. The company’s products also include ASP-4070 and ASP-0892 for treating allergy. The company also develops LAMP-vax technology vaccines that encode the expression of a fusion protein comprising the therapeutic antigen and the LAMP targeting protein. The company partners with academic centers and biotechnology companies to study the use of the UNITE platform in treating glioblastoma and acute myeloid leukemia. ITI is headquartered in Rockville, Maryland, the US.

Immunomic Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10
Immunomic Therapeutics Raises US$1 Million In Venture Financing 11
Immunomic Therapeutics Raises US$3 Million In Venture Financing 12
Immunomic Therapeutics Raises US$3 Million In Pre-Series B Financing Round 13
Immunomic Therapeutics Raises US$1.6 Million In Venture Financing 14
Immunomic Therapeutics Raises US$2.7 Million In Venture Financing 15
Immunomic Therapeutics Raises US$1.1 Million In Venture Financing 16
Immunomic Therapeutics Raises US$2 Million In Series A Financing 17
Partnerships 18
Immunomic Therapeutics Enters into Research Agreement with Duke University 18
Licensing Agreements 19
Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19
Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21
Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22
Equity Offering 23
Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23
Immunomic Therapeutics Inc – Key Competitors 24
Immunomic Therapeutics Inc – Key Employees 25
Immunomic Therapeutics Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Corporate Communications 27
Sep 10, 2018: Immunomic Therapeutics names Dr. Richard Ambinder to its Scientific Advisory Board 27
Dec 13, 2017: Immunomic Therapeutics Welcomes Key Thought Leader in Immuno-Oncology, Dr. Drew Pardoll, to Its Scientific Advisory Board 28
Nov 29, 2017: Immunomic Therapeutics’ Founder Appointed to Maryland Life Sciences Advisory Board 29
Jan 05, 2017: Immunomic Therapeutics’ Scientific Advisory Board Expansion 30
Product News 31
07/31/2017: Immunomic Therapeutics Welcomes New Oncology Advisor 31
Clinical Trials 32
Nov 22, 2017: Dr. Duane Mitchell Reports Findings of Study Aimed at Aggressive Brain Cancer 32
Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immunomic Therapeutics Raises USD4.6 Million in Venture Financing 10
Immunomic Therapeutics Raises US$1 Million In Venture Financing 11
Immunomic Therapeutics Raises US$3 Million In Venture Financing 12
Immunomic Therapeutics Raises US$3 Million In Pre-Series B Financing Round 13
Immunomic Therapeutics Raises US$1.6 Million In Venture Financing 14
Immunomic Therapeutics Raises US$2.7 Million In Venture Financing 15
Immunomic Therapeutics Raises US$1.1 Million In Venture Financing 16
Immunomic Therapeutics Raises US$2 Million In Series A Financing 17
Immunomic Therapeutics Enters into Research Agreement with Duke University 18
Immunomic Therapeutics Enters into Licensing Agreement with Trianni 19
Immunomic Therapeutics Enters into Licensing Agreement with Annias Immunotherapeutics 20
Astellas Pharma Enters into Licensing Agreement with Immunomic Therapeutics 21
Immunomic Therapeutics Enters into Licensing Agreement with Nature Technology 22
Immunomic Therapeutics Raises USD7 Million in Private Placement of Series A Preferred Shares 23
Immunomic Therapeutics Inc, Key Competitors 24
Immunomic Therapeutics Inc, Key Employees 25

List of Figures
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immunomic Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Immunomic Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.:企業の戦略・SWOT・財務分析
    SummaryGrupo Aeroportuario del Centro Norte, S.A.B. de C.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a …
  • Jadason Enterprises Limited (J03):企業の財務・戦略的SWOT分析
    Jadason Enterprises Limited (J03) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Acme United Corporation:企業の戦略・SWOT・財務分析
    SummaryAcme United Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key …
  • Alethia Biotherapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Alethia Biotherapeutics Inc (Alethia Biotherapeutics) is a biotechnology company that discovers and develops therapeutic products. The company’s products comprise AB-25E9 bone antiresorptive, AB-3A4 invasive carcinomas treatment products, and AB-16B5 EMT inhibitors. It also offers therapeuti …
  • Aviva plc:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Aviva plc Mergers and Acquisiti …
  • Vector Ltd (VCT):企業の財務・戦略的SWOT分析
    Vector Ltd (VCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Svenska Handelsbanken AB:企業の戦略・SWOT・財務情報
    Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report Summary Svenska Handelsbanken AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Avesthagen Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Avesthagen Limited Mergers and …
  • New Western Energy Corporation (NWTR):企業概要、財務及び戦略的SWOT分析
    Summary New Western Energy Corporation (New Western Energy) is an oil and gas and mineral exploration and production company. It focuses on the exploration, development and production from oil, gas and mineral properties. The company has acquired working interests in several producing oil wells in t …
  • Fujifilm Corporation:企業のM&A・提携動向(医療機器分野)
    Summary Fujifilm Corporation (Fujifilm), a subsidiary of Fujifilm Holdings Corporation, is a provider of imaging and information solutions. The company’s Imaging solutions comprise of color films, optical devices, digital cameras, photofinishing equipment and color paper, chemicals and services for …
  • Great Panther Silver Limited:企業の戦略・SWOT・財務情報
    Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report Summary Great Panther Silver Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Haci Omer Sabanci Holding A.S. (SAHOL):企業のM&A・提携動向(発電分野)
    Summary Haci Omer Sabanci Holding A.S. (Sabanci) is an industrial and financial conglomerate. It carries out banking, insurance, energy, retail, cement, automotive, tire and tire reinforcement materials businesses. The company has partnerships with various multinational business partners including A …
  • China Power International Development Limited (2380):企業財務及び戦略的SWOT分析
    Summary China Power International Development Limited (China Power), a subsidiary of State Power Investment Corporation is a power generation company that operates power plants. The company invests, develops, operates and manages coal-fired power, hydropower and wind power plants in Mainland China. …
  • Warburg Pincus LLC:戦略・SWOT・企業財務分析
    Warburg Pincus LLC - Strategy, SWOT and Corporate Finance Report Summary Warburg Pincus LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Leadiant Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Leadiant Biosciences Inc (Leadiant Biosciences), formerly Sigma-Tau Pharmaceuticals Inc, a subsidiary of Leadiant Biosciences SpA, is a pharmaceutical company that discovers and develops novel medicines. The company provides products such as abelcet, adagen, carnitor, cystaran, depocyt, matu …
  • Sysage Technology Co., Ltd. (6112):企業概要、財務及び戦略的SWOT分析
    Summary Sysage Technology Co., Ltd. (Sysage Tech) is a network solution provider. The company provides agent services for computer, communication equipment software and integrated application software. Its products include network application, systems and storage platforms, information security, inf …
  • XL Group Ltd:戦略・SWOT・企業財務分析
    XL Group Ltd - Strategy, SWOT and Corporate Finance Report Summary XL Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Mirna Therapeutics Inc (MIRN):企業のM&A・提携動向(医療分野)
    Summary Mirna Therapeutics Inc (Mirna) is a clinical stage biopharmaceutical company that develops and commercializes microRNA cancer therapeutics. The company through its microRNA replacement therapy technology develops products for cancer treatment. Its lead product, MRX34, developed in such a way …
  • American Water Works Company, Inc. (AWK):企業財務及び戦略的SWOT分析
    Summary American Water Works Company, Inc. (AWW) is a waste water utility company that offers fire protection and sanitation services. The company offers water and wastewater service, municipal and industrial contract, military services, residual and home owner services. Its home owner services prov …
  • Taekwang Industrial Co., Ltd. (003240):企業の財務及び戦略的SWOT分析
    Summary Taekwang Industrial Co., Ltd. (Taekwang) is a chemical company that manufacturers petrochemical, fiber and textile, and advanced materials. The company offers products such as purified terephthalic acid, propylene, acrylonitrile, sodium cyanide, ammonium sulphate, acetonitrile, hydrogen pero …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆